Jing Qiang
Vorsitzender bei Suzhou Sinovent Pharmaceutical Technology Co. Ltd.
Vermögen: 18 Mio $ am 30.04.2024
Profil
Jing Qiang is currently the Chairman of Suzhou Sinovent Pharmaceutical Technology Co. Ltd.
Prior to this, he worked as a Non-Executive Director at Sinomab Bioscience Ltd.
from 2020 to 2021.
From 2010 to 2018, he was a Managing Director at China International Capital Corp.
Ltd.
and before that, he worked as a Research Analyst at China International Capital Corp.
Ltd.
(Broker).
Mr. Qiang received his undergraduate degree from Shanghai Jiao Tong University in 2005 and his graduate degree from Fudan University in 2010.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
SINOMAB BIOSCIENCE LTD.
6,67% | 31.01.2024 | 72 823 636 ( 6,67% ) | 18 Mio $ | 30.04.2024 |
Aktive Positionen von Jing Qiang
| Unternehmen | Position | Beginn |
|---|---|---|
Suzhou Sinovent Pharmaceutical Technology Co. Ltd.
 Suzhou Sinovent Pharmaceutical Technology Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Suzhou Sinovent Pharmaceutical Technology Co. Ltd. is a private company that focuses on researching, developing, producing, and commercializing therapeutic drugs. The company is based in Suzhou, China. | Vorsitzender | - |
Ehemalige bekannte Positionen von Jing Qiang
| Unternehmen | Position | Ende |
|---|---|---|
| SINOMAB BIOSCIENCE LIMITED | Präsident | 30.11.2020 |
| CHINA INTERNATIONAL CAPITAL CORPORATION LIMITED | Vorstandsvorsitzender | 01.03.2018 |
China International Capital Corp. Ltd. (Broker)
 China International Capital Corp. Ltd. (Broker) Investment Banks/BrokersFinance China International Capital Corp. Ltd. (Broker) (CICC) is the brokerage division of China International Capital Corp. Ltd. which was established in 1995 as a strategic partnership between Chinese and international financial institutions and corporations. Headquartered in Beijing, CICC was the first joint venture investment bank in China. The firm's core business departments were investment banking, capital markets, sales & trading, research, fixed-income and asset management. CICC offers a range of brokerage services to international and domestic institutional and individual investors. In 2007 the firm set up a wholly-owned subsidiary specializing in private equity investments and focusing on buyout opportunities within China. | Analyst-Equity | - |
Ausbildung von Jing Qiang
| Shanghai Jiao Tong University | Undergraduate Degree |
| Fudan University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| SINOMAB BIOSCIENCE LIMITED | Health Technology |
| CHINA INTERNATIONAL CAPITAL CORPORATION LIMITED | Finance |
| Private Unternehmen | 2 |
|---|---|
Suzhou Sinovent Pharmaceutical Technology Co. Ltd.
Suzhou Sinovent Pharmaceutical Technology Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Suzhou Sinovent Pharmaceutical Technology Co. Ltd. is a private company that focuses on researching, developing, producing, and commercializing therapeutic drugs. The company is based in Suzhou, China. | Commercial Services |
China International Capital Corp. Ltd. (Broker)
China International Capital Corp. Ltd. (Broker) Investment Banks/BrokersFinance China International Capital Corp. Ltd. (Broker) (CICC) is the brokerage division of China International Capital Corp. Ltd. which was established in 1995 as a strategic partnership between Chinese and international financial institutions and corporations. Headquartered in Beijing, CICC was the first joint venture investment bank in China. The firm's core business departments were investment banking, capital markets, sales & trading, research, fixed-income and asset management. CICC offers a range of brokerage services to international and domestic institutional and individual investors. In 2007 the firm set up a wholly-owned subsidiary specializing in private equity investments and focusing on buyout opportunities within China. | Finance |
